Drug
Nivolumab or pembrolizumab
Nivolumab or pembrolizumab is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_3
1
25%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Recruiting2
Active, not recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (50.0%)
Phase 31 (50.0%)
Trials by Status
active_not_recruiting125%
unknown125%
recruiting250%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_3
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
NCT06488482
recruitingphase_1
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT05901285
active_not_recruiting
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
NCT03695952
unknown
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
NCT04306042
Clinical Trials (4)
Showing 4 of 4 trials
NCT06488482Phase 3
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
NCT05901285Phase 1
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT03695952
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
NCT04306042
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4